Phosphatidylethanol improves diagnostic accuracy of MASLD, MetALD, and ALD: Results from a prospective cohort study
Somaya Albhaisi, Brian P Lee · 2026
Read Phosphatidylethanol improves diagnostic accuracy of MASLD, MetALD, and ALD: Results from a prospective cohort study by Somaya Albhaisi, Brian P Lee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13542232.txt.
Description
Somaya Albhaisi and Brian P Lee published a 2026 commentary on a blood marker that could sharpen how fatty liver disease is sorted into types. Modern labels split the condition by cause: metabolic disease alone, metabolic disease combined with alcohol, or alcohol alone. That sorting still leans on what patients say they drink. The commentary examines a prospective cohort study by Torp and colleagues, which tested phosphatidylethanol, a direct alcohol marker in blood, against self-reports.
Among roughly 3,000 participants, about two in five people with heavy drinking histories had understated their intake when checked against the marker. The writers argue that an objective blood test can correct such misclassification and place patients in the right category. Correct placement matters because treatment and risk advice differ by cause, so the commentary supports wider use of the marker in liver clinics.
Catalog record
| CREATOR | Somaya Albhaisi, Brian P Lee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 8838 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |